Studies focusing on COVID-19 patients have identified sustained accessibility at exhaustion-related genes (e.g., TOX, Basic Leucine Zipper ATF-Like Transcription Factor (BATF)) and reduced accessibility at effector loci, even in convalescent phases (44–46). This evidence concerns the gene TOX and COVID-19.